Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gyre Therapeutics's Enterprise Value is $1,310.7 Mil.
Gyre Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Gyre Therapeutics's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Gyre Therapeutics's Enterprise Value is $1,310.7 Mil.
Gyre Therapeutics does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Gyre Therapeutics's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Gyre Therapeutics's Enterprise Value is $1,310.7 Mil.
Gyre Therapeutics does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Gyre Therapeutics's EV-to-Revenue at this moment.
Gyre Therapeutics Enterprise Value Historical Data
The historical data trend for Gyre Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Gyre Therapeutics Enterprise Value Chart
Gyre Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
Enterprise Value
-
-
1,964.42
Gyre Therapeutics Semi-Annual Data
Dec21
Dec22
Dec23
Enterprise Value
-
-
1,964.42
Competitive Comparison of Gyre Therapeutics's Enterprise Value
For the Biotechnology subindustry, Gyre Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Enterprise Value falls into.
Gyre Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Gyre Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (NAS:GYRE) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Gyre Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Gyre Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Gyre Therapeutics (Gyre Therapeutics) Business Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GYRE has been successfully added to your